Biopharmaceutical company Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) said on Friday that NHS England has implemented the use of Evkeeza (evinacumab) for eligible adults and adolescents with homozygous familial hypercholesterolemia (HoFH).
This decision follows positive guidance from the National Institute for Health and Care Excellence (NICE).
Evkeeza, a monoclonal antibody that inhibits the ANGPTL3 protein, is designed to lower levels of LDL-C, or bad cholesterol. The drug will be available at seven hospital trusts in England, providing a significant treatment option for patients with this rare and serious condition.
HoFH is a genetic disorder characterised by extremely high levels of LDL-C, which can lead to premature heart disease.
Boston Scientific receives FDA clearance for Asurys fluid management system
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Lupin reports tentative FDA approval for Pitolisant Tablets
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
GE HealthCare's Photonova Spectra gains FDA clearance
Futura Medical reports positive home user test results for Eroxon and Intense variant